Conference Coverage

MOMENTUM 3 HeartMate 3 LVAD ‘practice changing’

Dr. Hossein Almassi, FCCP

G. Hossein Almassi, MD, FCCP, comments: The reported 2- year follow-up results of MOMENTUM 3 trial on the new generation HeatMate-III magnetically levitated LVAD gives more hope to patients with end-stage heart failure for a better quality of life and longer survival and opens new doors for potentially becoming an alternative to cardiac transplantation for patients with a long waiting time on the transplant list.


 

REPORTING FROM ACC 18

SOURCE: Mehra M et al. ACC 18.

Pages

Recommended Reading

Heart attacks soar in young IBD patients
MDedge Cardiology
Postmenopausal women: Walk farther and faster to reduce heart failure risk
MDedge Cardiology
VEST: Closer tailoring might boost wearable cardioverter defibrillator’s benefit
MDedge Cardiology
ODYSSEY Outcomes results build on FOURIER
MDedge Cardiology
ODYSSEY Outcomes trial redefines secondary cardiovascular prevention
MDedge Cardiology
Ticagrelor noninferior to clopidogrel in terms of major bleeds in STEMI
MDedge Cardiology
Genotype did not significantly affect evacetrapib response
MDedge Cardiology
CECCY: Carvedilol didn’t curb cardiotoxicity in breast cancer patients
MDedge Cardiology
MDedge Daily News: Improving wearable cardioverter defibrillators
MDedge Cardiology